LANDIOLOL, AN ULTRA-SHORT ACTING BETA-1 BLOCKER, FOR PREVENTING POSTOPERATIVE LUNG CANCER RECURRENCE: STUDY PROTOCOL FOR A PHASE III, MULTICENTER RANDOMIZED TRIAL WITH TWO PARALLEL GROUPS OF PATIENTS

Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients

Abstract Background Recurrence of cancer after curative surgery is a major problem after most cancer treatments.Increased sympathetic activity during the perioperative period could promote cancer cell invasion to blood vessels and angiogenesis, resulting in cancer metastasis.Recent studies showed that use of Tie-Dye T-Shirt beta blockers can be ass

read more